Phenotypic heterogeneity in severe hemophilia

Journal of Thrombosis and Haemostasis

Volumn 5, Issue SUPPL. 1, 2007, Pages 151-156

  van den Berg, H M ^a,b   de Groot, P H G ^b   Fischer, K ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Clinical phenotype; Coagulation; Severe haemophilia; Thrombin generation

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; INTERLEUKIN 10; PROTEIN C; PROTEIN S; PROTHROMBIN; THROMBIN; VON WILLEBRAND FACTOR;

ARTHROPATHY; BLEEDING TENDENCY; BLOOD GROUP O; CHROMOSOME 22; CHROMOSOME INVERSION; CLINICAL FEATURE; DISEASE SEVERITY; DRUG HALF LIFE; ENVIRONMENTAL FACTOR; FIBRINOLYSIS; GENE MUTATION; HEMARTHROSIS; HEMOPHILIA A; HUMAN; INTRON; LIFESTYLE; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; RELIABILITY; REVIEW; RISK FACTOR; THROMBIN TIME; THROMBOCYTE; THROMBOPLASTIN TIME;

BLOOD COAGULATION; HEMOPHILIA A; HEMORRHAGE; HUMANS; PHENOTYPE; SEVERITY OF ILLNESS INDEX; THROMBIN;

EID: 34250702800     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02503.x     Document Type: Review

References (40)

1. Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Review. Lancet 2003; 24: 1801-9.
2. Van Dijk K, van der Bom JG, Fischer K, Grobbee DE, Van den Berg HM. Variability in clinical phenotype of severe haemophilia; the role of the first joint bleed. Haemophilia 2005; 11: 438-43.
3. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994; 236: 391-9.
4. Onwuzurike N, Warrier I, Lusher JM. Types of bleeding seen during the first 30 months of life I children with severe hemophilia A and B. Haemophilia 1996; 2: 137-40.
5. Ljung R, Petrini P, Nilsson IM. Diagnostic symptoms of severe and moderate haemophilia A and B. Acta Paediatrc Scand 1990; 79: 196-200.
6. Fischer K, Van der Bom JG, Mauser-Bunschoten EP, Roosendaal G, Beek FJ, De Kleijn P, Grobbee DE, Van den Berg HM. Endogenous clotting factor activity and long-term outcome in patients with moderate haemophilia. Thromb Haemost 2000; 84: 977-80.
7. Plug I, Van der Bom JG, Peters M, Mauser-Bunschoten EP, de Goede-Bolder A, Heijnen L, Smit C, Zwart-van Rijkom JE, Willemse J, Rosendaal FR. Thirty years of hemophilia treatment in the Netherlands, 1972-2001. Blood 2004; 104: 3494-500.
8. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years experience of prophylactic therapy in severe haemophilia A and B. J Int Med 1992; 232: 25-32.
9. Van Dijk K, van der Bom JG, Lenting PJ, De Groot PhG, Mauser-Bunschoten EP, Roosendaal G, Grobbee DE, Van den Berg HM. Factor VIII half-life and clinical phenotype of severe hemophilia A. Haematologica 2005; 90: 494-8.
10. Rainsford SG, Hall A. A three-year study of adolescent boys suffering from haemophilia and allied disorders. B J Haematol 1973; 24: 539-51.
11. Molho P, Rolland N, Lebrun T, Dirat G, Courpied JP, Croughs P, Duprat I, Sultan Y. Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France. The French Study Group. Haemophilia 2000; 6: 23-32.
12. Mann KG. Biochemistry and physiology of blood coagulation. Thromb Haemost 1999; 82: 165-74.
13. Mann KG, Butenas S, Brummel K. The dynamics of thrombin formation. Atheroscler Thromb Vasc Biol 2003; 23: 17-25.
14. Nichols WC, Amano K, Cacheris PM, Figueiredo MS, Michaelides K, Schwaab R, Hoyer L, Kaufman RJ, Ginsburg D. Moderation of hemophilia A phenotype by the factor V R506Q mutation. Blood 1996; 88: 1183-7.
15. Escuriola-Ettingshausen C, Halimeh S, Kurnik K, Schobess R, Wermes C, Junker R, Kreuz W, Pollmann H, Nowak-Gottl U. Symptomatic onset of severe hemophilia A in childhood is dependent on the presence of prothrombotic risk factors. Thromb Haemost 2001; 85: 218-20.
16. Fijnvandraat K, Peters M, ten Cate JW. Inter-individual variation of half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand antigen levels. Br J Haematol 1995; 91: 474-6.
17. Vlot AJ, Mauser-Bunschoten EP, Zarkova AG, Haan E, Kruitwagen CL, Sixma JJ, van den Berg HM. The half-life of infused factor VIII is shorter in hemophiliac patients with blood group O than in those with blood group A. Thromb Haemost 2000; 83: 65-9.
18. Pencharz PB. Drug dosing in children - special consideration. Haemophilia 2006; 12 (Suppl. 4): 30-2.
19. Schwaab R, Oldenburg J, Tuddenham EG, Brackmann HH, Olek K. Mutations in haemophilia A. Br J Haematol 1993; 83: 450-8.
20. Goodeve AC, Peake IR. The molecular basis of hemophilia a: genotype-phenotype relationships and inhibitor development. Semin Thromb Hemost 2003; 29: 23-30.
21. Oldenburg J. Mutation profiling in haemophilia A. Thromb Haemost 2001; 85: 577-9.
22. Goodeve AC, Preston FE, Peake IR. Factor VIII gene rearrangements in patients with severe haemophilia A. Lancet 1994; 343: 329-30.
23. Shima M, Matsumato T, Fukuda K, Kubota I, Tanaka I, Nishiya K, Giles AR, Yoshioka A. The utility of activated partial thromboplastin time (aPTT) clot waveform analysis in the investigation of hemophilia A patients with very low levels of factor VIII activity (FVIII: C). Thromb Haemost 2002; 87: 436-41.
24. Hemker HC, Beguin S. Phenotyping the clotting system. Thromb Haemost 2000; 84: 747-51.
25. Hemker HC, Giesen PL, Ramjee M, Wagenvoord R, Beguin S. The thrombogram: monitoring thrombin generation in platelet-rich plasma. Thromb Haemost 2000; 83: 589-91.
26. Sorensen B, Ingerslev J. Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa J Thromb Haemost 2004; 2: 102-10.
27. Dargaud Y, Beguin S, Lienhart A, Al Dieri R, Trzeciak C, Bordet C, Hemker HC, Negrier C. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost 2005; 93: 475-80.
28. Grunewald A, Siegemund A, Grunewald M, Konegan A, Koksch M, Griesshammer M. Paradoxysmal hyperfibrinolysis is associated with a more intensely haemorrhagic phenotype in severe congenital haemophilia. Haemophilia 2002; 8: 768-75.
29. Lisman T, Mosnier LO, Lambert T, Mauser-Bunschoten EP, Meijers JC, Nieuwenhuis HK, de Groot PG. Inibition of fibrinolysis by recombinant factor VIIa in plasma form patients with severe hemophilia A. Blood 2002; 99: 175-9.
30. Heijnen L, Mauser-Bunschoten EP, Roosendaal G. Participation in sports by Dutch persons with haemophilia. Haemophilia 2000; 6: 537-46.
31. Harris S, Boggio LN. Exercise may decrease further destruction in the adult haemophilic joint. Haemophilia 2006; 12: 237-40.
32. Hilberg T, Herbsleb M, Puta C, Gabriel HHW, Schramm W. Physical training increases isometric muscular strength and proprioceptive performance in haemophilic subjects. Haemophilia 2003; 9: 86-93.
33. Huizinga TW, Keijsers V, Yanni G, Hall M, Ramage W, Lanchbury J, et al. Are differences in interleukin 10 production associated with joint damage? Rheumatology 2000; 39: 1180-8.
34. Verhoef CM, Van Roon JA, Vianen ME, Bijlsma JW, Lafeber FP, Pitzalis C, Drossaers-Bakkers WK, Westendorp RG, Breedveld FC, Panay G, Verweij CL. Interleukin 10 (IL-10), not IL-4 or interferon-gamma production, correlates with progression of joint destruction in rheumatoid arthritis. J Rheumatol 2001; 28: 1960-6.
35. Butenas S, van 't Veer C, Cawthern K, Brummel KE, Mann KG. Models of blood coagulation. Blood Coagul Fibrinolysis 2000; 11(Suppl. 1): S9-13.
36. Van Dijk K, van der Bom JG, Fischer K. Do prothrombotic factors influence clinical phenotype of severe haemophilia? A review of the literature. Thromb Haemost 2004; 92: 305-10.
37. Schlachterman A, Schuettrumpf J, Liu JH, Furlan Freguia C, Toso R, Poncz M, Camire RM, Arruda V. Factor V Leiden improves in vivo hemostasis in murine hemophilia models. J Thromb Haemost 2006; 4: 925.
38. Bassus S, Wegert W, Krause M, Escuriola-Ettinghausen C, Siegemund A, Petros S, Scholz T Scharrer I, Kreuz W, Engelmann L, Kirchmaier CM. Platelet-dependent coagulation assays for factor VIII efficacy measurments after substitution therapy in patients with haemophilia A. Platelets 2006; 17: 378-84.
39. Bos HA, Meijerman DWE, Van der Zwaan C, Mertens K. Does activated protein C-resistant factor V contribute to thrombin generation in haemophilic plasma? J Thromb Haemost 2005; 3: 522-30.
40. Van Dijk K, van der Bom JG, Fischer K, de Groot PG, van den Berg HM. Phenotype of severe hemophilia A and plasma levels of risk factors for thrombosis. J Thromb Haemost 2007;5: 1062-65.